Transaction details
Crinetics Pharmaceuticals (NASDAQ: CRNX) Chief Financial Officer Tobin Schilke sold 6,713 shares of the companys common stock on March 3, 2026. The shares were disposed of at an average price of $39.67, producing total proceeds of $266,304. Reported trade prices ranged from $39.67 to $39.74.
Context and ownership
At the time of the report, the market price for Crinetics stock was $39.51, and the shares had declined nearly 10% over the prior week. Following the transaction, Schilke retains direct ownership of 78,121 shares.
Reason for the sale and mechanics
The disposition was conducted to cover tax obligations stemming from restricted stock units that vested on March 10, 2025. Crinetics disclosed that the trade was executed pursuant to a pre-arranged Rule 10b5-1 trading plan.
Recent company performance
Crinetics recently released fourth quarter 2025 financial results that surpassed consensus expectations. The company reported an actual earnings per share (EPS) of -$1.29, compared with a forecasted EPS of -$1.34. Revenue for the quarter totaled $6.1 million, ahead of analysts expectations of $4 million.
Analyst guidance and launch metrics
One market analyst cut the firms price target to $96 from $105 but retained a Market Outperform rating. That revision was informed by early launch metrics for the companys drug Palsonify, which the analyst believes shows substantial adoption potential in the treatment of acromegaly. Physician surveys cited in the update indicate an expected adoption rate in the United States of roughly 20% to 30%, implying a U.S. market opportunity between $670 million and $1 billion. This range is notably higher than the analysts own peak sales projection of about $560 million.
Valuation note
An independent analysis noted that, at a $4.14 billion valuation, Crinetics may be trading below its intrinsic value and that overall analyst sentiment is positive. These views sit alongside the recent insider sale and the companies reported operating results.
Takeaway
The insider sale was disclosed as a tax-driven event executed under an established trading plan. It coincides with quarterly results that beat expectations and with mixed but generally constructive analyst commentary tied to early commercial metrics for Palsonify.